Results about: tech transfer
IRB Barcelona and Merus form a research collaboration to develop antibodies targeting the tumor microenvironment
The research collaboration will combine Merus’ Biclonics technology platform and unique cell and animal models at the Colorectal Cancer Laboratory led by Eduard Batlle to investigate the stroma.
Compound IPR19, a drug to stop the progression and reverse the cognitive deficits associated with schizophrenia.
A study at IRB Barcelona has identified the cells responsible for initiating and promoting metastasis in several types of human tumours.
Their results show that the protein CD36, which absorbs fat from the cell membrane, is an essential factor that determines whether tumour cells become metastatic.
In the absence of CD36, the human tumours analysed did not develop metastasis. In addition, the inhibition of this protein also dramatically reduced the size of existing metastases.
Mice given a high-fat diet developed the most aggressive metastases. The study reports that the metastatic process is enhanced by fat intake.
IRB Barcelona will co-develop antibodies against CD36 with the potential to treat patients.
IRB Barcelona fosters entrepreneurship among its young scientists. Two postdoctoral fellows tell in vivo about their experience of learning how to deal with markets, patents and venture capitalists.